Palmaz stent deployment is a useful method for subclavian and brachiocephalic arterial occlusive disease. We evaluated restenosis or intimal thickening after Palmaz stent deployment for nine lesions of subclavian or brachiocephalic arterial occlusive disease focusing on stent diameter, atheroma thickness near the stent, and degree of coverage for the lesion. Follow up DSA and IVUS at 5-14 months (mean 9) after therapy showed no significant changes tn the size or shape of the stent itself There were two lesions of thin in-stent intimal hyperplasia and five lesions of thick hyperplasia.
Introduction
Percutaneous transluminal angioplasty (PTA) is a useful therapy for occlusive disease of the supraaortic arch arteries. Using Palmaz stent, PTA becomes more safe and successful, and long-term patency is dramatically improved. Although initial technical success of Palmaz stent deployment is obtained, there is some incidence of restenosis. To clarify the cause of restenosis after Palmaz stent deployment for subclavian and brachiocephalic artery occlusive lesions, we analyzed several factors.
Materials and methods
Of twenty-four Palmaz stent deployments for subclavian & brachiocephalic artery occlusive disease (ASO), 9 lesions in 8 cases having initial and FlU IVUS were analyzed. The patients were 6 males and 2 females, aged between 52 to 80 years (average 68). There were eight lesions of the left subclavian artery and one lesion of the brachiocephalic artery including two occlusions and seven stenoses (50 -99% stenosis). Access to the lesions was performed through a femoral approach in 7 cases, and through femoral and brachial arteries in 2 cases. The length of the Palmaz stent ranged from 20 to 39 mm, with the diameter of the deployed stent ranging from 6 to 9 mm. IVUS was performed with an Endosonics 20 MHz electric scan probe or CVIS insight 20 MHz mechanical scan probe.
The following items were analyzed:
As initial technical items, the success rate of stent deployment and the complication rate were determined. As follow up items, stent deformity, restenosis, and degree of intimal hyperplasia were analyzed. The degree of intimal hyperplasia in the stent was classified into three categories; none (thickness of intimal hyperplasia is under 0.2 mm), mild (0.2 -0.5 mm), and moderate (0.5 mm and over). Relations between intimal hyperplasia and stent diameter, Table 1 Relationship between intimal hyperplasia and stent diameter atheroma thickness at the immediately distal side, and degree of coverage of lesion by the stent were also analyzed. The thickness of the atheroma at the immediately distal side of stent was observed by initial IVUS.
Results
Palmaz stent deployment was successful in all cases. The occlusions and stenoses completely disappeared in all cases. There was no neurological complication due to stent deployment. Thickness of atheroma at the immediately distal end of the stent and its relative ratio to media -media diameter ranged 0.1 to 1.0 mm (mean 0.5 mm) and 1 to 23% (median 5.3%), respectively.
Follow up DSA and IVUS were obtained at 5-14 months after stent deployment (mean 9 months). In the follow up study, IVUS and DSA showed no stent deformity in any cases. Intimal hyperplasia was observed in seven of nine lesions, but restenosis (over 50% reduction of lumen diameter) was observed in only one case. The type of intimal hyperplasia was as follows: thin partial (one case), thin whole (one case), thick partial (three cases), and thin whole (two cases).
The relationship between stent diameter and degree of intimal hyperplasia was shown in table 1. There was no close relationship between them.
The relationship between atheroma size (relative thickness) and degree of intimal hyperplasia was shown in table 2. There was no clear relationship between either.
The relationship between degree of coverage of lesion by stent and degree of intimal hyperplasia was shown in table 3. In the cases of complete coverage, there was only one case (25%) of moderate intimal hyperplasia. In the cases of incomplete coverage, there were four cases (80%) of moderate intimal hyperplasia.
Illustrative case

Left subclavian artery occlusion
The patient is a 72-year-old man with lower limb ischemic signs due to arteriosclerosis obliterans (ASO). DSA shows long segment complete occlusion of the left subclavian artery and subclavian steal phenomenon (figure lA). 
Discussion
Numerous reports and our previous study have established the safety and the efficacy of Palmaz stent deployment for subclavian and brachiocephalic occlusive disease due to AS01, 2,3. Stent deployment for arterial occlusive disease of other vessels like the iliac arteries is also safety and effective, but there is some incidence of restenosis 4,5,6,7. The development of stenotic lesions distal to a stent has been reported to occur at a rate of approximately 5% per year 4 ,5 . Restenosis after stent implantation for iliac artery occlusive disease showed a relationship with small vessel size, and involved distal arterial (superficial femoral artery) flow was also associated with restenosis 7 . In coronary artery stent implantation, the strongest risk factor for restenosis was found to be small vessel size or stent lumen cross sectional area 8,9. Compared with iliac arterial occlusive disease, subclavian arterial occlusive disease is characterized relatively short segmental stenosis and good distal arterial flow. All cases of our series showed good distal subclavian or brachiocephalic arterial flow. In our study, restenosis (50% or greater diameter reduction) was found in one of nine cases in the follow-up study (5-14 months, mean 9). We have analyzed the relations between intimal hyperplasia and stent diameter, atheroma thickness at the immediately distal side, and degree of coverage of lesion by stent.
On the basis of the results of our analysis, there was no close relationship between stent diameter and degree of intimal hyperplasia. Atheroma size (relative thickness) and degree of intimal hyperplasia showed no clear relationship either.
Although only the degree of lesion coverage by stent seems to have some relationship to the degree of intimal hyperplasia in our study, we could not obtain a statistically significant result. Other factors like tobacco consumption or medication for anticoagulation after stent deployment may play a role.
Conclusion
There is some incidence of restenosis after Palmaz stent deployment for occlusive disease of the subclavian or brachiocephalic artery. Although incompleteness of lesion coverage by stent may be a cause, accumulation of more cases is necessary.
